News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Former Genentech, Inc. (DNA) Executive Vice President And CFO Louis J. Lavigne, Jr. Joins The Faculty Of Babson Executive Education's Bio-Pharma: Mastering The Business Of Science Program

10/19/2005 5:09:10 PM

WELLESLEY, Mass., Aug. 26 /PRNewswire/ -- Former Genentech Executive Vice President and CFO Louis J. Lavigne, Jr. joins the faculty of Babson Executive Education's Bio-Pharma: Mastering the Business of Science program.

The program, which is designed to help bio-business professionals contribute more to their company by building skills and knowledge in the areas of strategy, finance, marketing, and leadership in the biotechnology and pharmaceutical industries, will take place on September 26-30, 2005, April 24- 28, 2006, and October 23-27, 2006.

"The addition of Lou Lavigne to our faculty team further strengthens our ability to meet the needs of program participants," says Faculty Director, Ken Matsuno. "By marrying the practical dimension of his professional experiences with the superb knowledge and skills of our talented faculty, we offer an extremely powerful, high-impact program."

Named Best CFO in Biotech in 2005 in the Institutional Investor survey, Lavigne retired from his role as Executive Vice President and Chief Financial Officer of Genentech in March 2005 after 23 years with the company. He was named Executive Vice President in March of 1997. He joined Genentech in July 1982 and was named controller in 1983 and, in this position, built Genentech's operating financial functions. In 1986, he was promoted to Vice President and assumed the CFO position in September 1988. He was named Senior Vice President in July 1994. Lavigne was a member of Genentech's Executive Committee, Chairman of its 401K Plan Committee, and responsible for its Financial, Corporate Relations, and Information Technology groups.

Genentech achieved significant growth during Lavigne's tenure; the company's annual revenues stood at $40 million when he was named Controller in 1983, around $300 million when he became CFO in 1988 and were over $4.6 billion in 2004. Measured by market capitalization, Genentech recently became the largest biotech in the world.

"To be invited to participate in such a reputable program is exciting," says Lavigne. "I'm thrilled with the opportunity to share my personal experiences in the industry and exchange ideas with professionals from other bio businesses."

Prior to joining Genentech, Mr. Lavigne held various financial management positions with Pennwalt Corporation, a chemical and pharmaceutical company.

Lou Lavigne is a member of the Board of Directors of the following public companies: Allergan Inc, Arena Pharmaceutical, Inc., Equinix, BMC Software, Kyphon and LifeMasters Supported Self Care, Inc., a private company.

Mr. Lavigne earned a bachelor's degree in business administration from Babson College in 1969 and a master's degree in business administration from Temple University in 1976.

An interview with Lou Lavigne concerning Genentech: Success and the Future of Biotechnology is available in Babson Insight, Babson Executive Education's top-ranked e-newsletter (

About Babson's Bio-Pharma: Mastering the Business of Science Program

Babson's Bio-Pharma program covers the core business and management concepts that are particularly relevant to the biotechnology and pharmaceutical industries. It is targeted to managers in marketing, research, development, finance, business development, human resources, and manufacturing. The intensive program is of key significance to bio-pharma scientists who want to enhance their managerial effectiveness to navigate their company's strategic, financial, marketing, and leadership issues. The program uses a variety of learning approaches, including interactive lectures, panel discussions, case studies, and group exercises. Each session is designed to actively involve participants in the classroom discussion, exploring present and future business and individual development issues in the bio- pharma industry. At the end of the program, participants complete a group project and present their findings regarding the future of the industry.

Program Outline: * Understanding the Bio-Pharma Business and Industry Environment * Analytical Tools and Challenges in Finance and Marketing * Planning the Unplannables: Evaluating Bio-Pharma Projects and New Product Development Strategies * The Changing Health Care Environment and Effective Leadership * Projecting the Future: Industry and Individual

The program is led by distinguished Babson faculty, many of whom are experts in the field of life sciences.

Kenichi Matsuno, Faculty Director: Associate Professor of Marketing, Irving Pike Term Chair, Babson College; MBA Darden Graduate School of business Administration, University of Virginia; PhD, University of Tennessee. Matsuno has taught executive education programs for companies such as Novartis, Zeneca, DSM, Nomura Research Institute, Simpson Gumperts & Heger, S&B Foods, and Toshiba. Prior to his academic career, he worked at Eli Lilly & Co., where he held positions in international pharmaceutical market research, field sales, and new product development.

Elaine E. Allen: Associate Professor of Statistics and Entrepreneurship, Kevern R. Joyce Chair, Babson College; MA, University of Evansville; PhD, Cornell University. Allen founded several companies and held executive positions in the health care and biotechnology industries, including at Centocor, ARIAD Pharmaceuticals, and MetaWorks Inc. Her entrepreneurial activities include starting StatSystems, a medical device company; ARIAD Pharmaceuticals, a publicly held biotechnology company; and Pondview Associates, a consulting firm.

Gaurab Bhardwaj: Assistant Professor of Strategy and Management, Babson College; MBA, Northeastern University; PhD, University of Pittsburgh. His current research, writing, and professional presentations are on decision making by scientists for inventions, how scientist-entrepreneurs conceive of entirely new businesses, links between science and strategy for long-term corporate growth, and managing science as a search portfolio.

Allan R. Cohen: Professor of Management, Edward A. Madden Distinguished Professor in Global Leadership, Babson College; MBA, DBA, Harvard University. A noted author, speaker, and consultant, Cohen is the coauthor of the best- selling books Managing for Excellence and Influence Without Authority. His latest book with David Bradford, Power Up: Transforming Organizations through Shared Leadership, was selected as one of the best leadership books of 1998 by the Management General Web site.

Michael A. Goldstein: Associate Professor of Finance, Joseph Winn Term Chair, Babson College; MA, MBA, PhD, Wharton School, University of Pennsylvania. From 1997 to 1998, Goldstein was the visiting economist at the New York Stock Exchange, the eighth academician to hold this one-year post. He has served on an SEC roundtable and advised the national economic adviser to the President of the United States.

More information about the program can be found at

About Babson Executive Education

Babson Executive Education is committed to developing talent and capability in the life science industry. As a leader in designing and delivering executive education programs for more than 25 years, Babson has worked closely with life science companies to provide custom, open enrollment, and consortium programs. Babson Executive Education is ranked among the top 10 providers worldwide by both BusinessWeek and the Financial Times.

This news release was issued on behalf of Newswise(TM). For more information, visit

Babson College

CONTACT: Barbara Spies Blair, +1-781-239-4621,, orMichael Chmura, +1-781-239-4549,, both of Babson College

Read at

comments powered by Disqus